Maija Hollmén creator_y5s5mst7ufcwpmamlqb5qdns3y

Given name Maija
Surname Hollmén

Releases

This creator has contributed to:

2019-02-12 Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors
published | article-journal
doi:10.1158/1078-0432.ccr-18-3016
2016 Transcriptional profiling of macrophage and tumor cell interactions in vitro
published | article-journal | CC-BY-NC-ND
doi:10.1016/j.gdata.2016.02.009
2019-03-29 Clever-1 contributes to lymphocyte entry into the spleen via the red pulp
published | article-journal
doi:10.1126/sciimmunol.aat0297
2020-11-13 Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors
unknown status | post
doi:10.1101/2020.11.11.20227777
2021-03-27 A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema
published | article-journal
doi:10.17863/cam.66411
2021-03-24 A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema
published | article-journal | CC-BY
doi:10.3390/ijms22073313
2022-11-28 Biallelic STAB1 pathogenic variants cause hereditary hyperferritinemia
unknown status | post
doi:10.1101/2022.11.24.22282670
2021-06-02 Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial
published | article-journal
doi:10.1158/1078-0432.ccr-20-4862
2022-05-02 Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers
published | article-journal
doi:10.1158/1535-7163.mct-21-0840
2023-11-14 Dimeric IgA specifically disables intracellular mutated oncodrivers
published | article-journal
doi:10.1016/j.immuni.2023.10.014
2024-01-03 Table S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935436
2024-01-03 Data from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.c.7005684.v1
2024-01-03 Table S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935439.v1
2024-01-03 Figure S3 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935454
2024-01-03 Figure S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935460
2024-01-03 Figure S5 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935448.v1
2024-01-03 Figure S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935460.v1
2024-01-03 Figure S7 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935442.v1
2024-01-03 Figure S4 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935451
2024-01-03 Table S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935439
2024-01-03 Table S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935436.v1
2024-01-03 Figure S6 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935445.v1
2024-01-03 Figure S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935457.v1
2024-01-03 Figure S3 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935454.v1
2024-01-03 Figure S7 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935442
2024-01-03 Figure S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935457
2024-01-03 Figure S6 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935445
2024-01-03 Data from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.c.7005684
2023-11-03 Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments
published | article-journal
doi:10.1158/2326-6066.cir-23-0350
2023-04-18 Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial
unknown status | post
doi:10.1101/2023.04.17.23288693
2023-05-12 Respiratory Complex I Regulates Dendritic Cell Maturation in Explant Model of Human Tumor Immune Microenvironment
unknown status | post
doi:10.1101/2023.05.10.539944
2024-05-14 Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses
unknown status | post
doi:10.1101/2024.05.11.593502
2024-06-03 Clinical landscape of macrophage-reprogramming cancer immunotherapies
published | article-journal
doi:10.1038/s41416-024-02715-6
2024-10-27 Secreted Clever-1 Modulates T Cell Responses and Impacts Cancer Immunotherapy Efficacy
unknown status | post | CC-BY-NC-ND
doi:10.1101/2024.10.23.619796
2024-01-03 Figure S4 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935451.v1
2024-01-03 Figure S5 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status | post | CC-BY
doi:10.1158/2326-6066.24935448
Lookup Links
wikidata.org
VIAF
dblp (CS)
Google Scholar
Catalog Record
Revision: f2f0650b-9874-4577-967d-ebfe6b293b67
API URL: JSON